JP2015514700A - 婦人科疾患の治療方法 - Google Patents

婦人科疾患の治療方法 Download PDF

Info

Publication number
JP2015514700A
JP2015514700A JP2015501044A JP2015501044A JP2015514700A JP 2015514700 A JP2015514700 A JP 2015514700A JP 2015501044 A JP2015501044 A JP 2015501044A JP 2015501044 A JP2015501044 A JP 2015501044A JP 2015514700 A JP2015514700 A JP 2015514700A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
active metabolite
progesterone receptor
composition suitable
intravaginal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015501044A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514700A5 (enExample
Inventor
ゴトラン，ジャン−ピエール
ボウヤ，ヴァレリエ
ルーマイエ，エルネス
Original Assignee
プレグレム ソシエテ アノニム
プレグレム ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレグレム ソシエテ アノニム, プレグレム ソシエテ アノニム filed Critical プレグレム ソシエテ アノニム
Publication of JP2015514700A publication Critical patent/JP2015514700A/ja
Publication of JP2015514700A5 publication Critical patent/JP2015514700A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2015501044A 2012-03-23 2013-03-22 婦人科疾患の治療方法 Pending JP2015514700A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261614785P 2012-03-23 2012-03-23
US61/614,785 2012-03-23
EP12160956.4A EP2641602A1 (en) 2012-03-23 2012-03-23 Method for treating gynecological diseases
EP12160956.4 2012-03-23
PCT/IB2013/052274 WO2013140372A1 (en) 2012-03-23 2013-03-22 Method for treating gynecological diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018023604A Division JP2018109025A (ja) 2012-03-23 2018-02-13 婦人科疾患の治療方法

Publications (2)

Publication Number Publication Date
JP2015514700A true JP2015514700A (ja) 2015-05-21
JP2015514700A5 JP2015514700A5 (enExample) 2016-05-19

Family

ID=45976689

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015501044A Pending JP2015514700A (ja) 2012-03-23 2013-03-22 婦人科疾患の治療方法
JP2018023604A Pending JP2018109025A (ja) 2012-03-23 2018-02-13 婦人科疾患の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018023604A Pending JP2018109025A (ja) 2012-03-23 2018-02-13 婦人科疾患の治療方法

Country Status (18)

Country Link
US (1) US10441534B2 (enExample)
EP (3) EP2641602A1 (enExample)
JP (2) JP2015514700A (enExample)
KR (1) KR20140138824A (enExample)
CN (1) CN104203246A (enExample)
AU (1) AU2013236960B2 (enExample)
CA (1) CA2864073A1 (enExample)
CO (1) CO7111317A2 (enExample)
EA (1) EA031488B1 (enExample)
GE (1) GEP201706696B (enExample)
HK (1) HK1199827A1 (enExample)
MX (1) MX369520B (enExample)
MY (1) MY172530A (enExample)
NZ (1) NZ630011A (enExample)
SG (1) SG11201404921QA (enExample)
TW (2) TW201832767A (enExample)
WO (1) WO2013140372A1 (enExample)
ZA (1) ZA201407575B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112909A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP6906525B2 (ja) 2015-12-23 2021-07-21 オリック ファーマシューティカルズ，インク． グルココルチコイド受容体の阻害剤
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017165707A1 (en) * 2016-03-24 2017-09-28 Juniper Pharmaceuticals, Inc. Vaginal administration of agents for treating and preventing pain associated with gynecological medical procedures
PT3523315T (pt) 2016-10-07 2021-04-29 Oric Pharmaceuticals Inc Inibidor de recetor de glucocorticoide
US20240122885A1 (en) * 2021-02-12 2024-04-18 The Regents Of The University Of California Endometriosis-Related Methods and Compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510949A (ja) * 2008-01-29 2011-04-07 ラボラトワール・アシュエールア−ファルマ 子宮筋腫を治療するためのウリプリスタルの使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3920805A (en) 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
US4155991A (en) 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
IL48277A (en) 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US3995634A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US3995633A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US3991760A (en) 1975-12-02 1976-11-16 The Procter & Gamble Company Vaginal medicament dispensing means
US4286587A (en) 1978-10-11 1981-09-01 Alza Corporation Vaginal drug delivery system made from polymer
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4250611A (en) 1979-04-19 1981-02-17 Alza Corporation Process for making drug delivery device with reservoir
EP0180264A1 (en) 1984-10-12 1986-05-07 Akzo N.V. Release system for two or more active substances
NL8500470A (nl) 1985-02-19 1986-09-16 Achel Homesteel Pvba Intravaginaal orgaan.
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FI95768C (fi) 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
AU2004217988C1 (en) 2003-02-28 2010-06-03 Southwest Foundation For Biomedical Research Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
JP5017109B2 (ja) 2004-07-09 2012-09-05 ザ・ポピュレイション・カウンシル，インコーポレイテッド プロゲステロン受容体モジュレーターを含有する徐放性組成物
SI2148681T1 (sl) * 2007-04-20 2016-07-29 Preglem S.A. Selektivni modulatorji progesterona v zdravljenju maternične krvavitve
ES2648640T3 (es) * 2008-02-04 2018-01-04 Ferring B.V. Anillos intravaginales monolíticos que comprenden progesterona y métodos de fabricación y usos de los mismos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510949A (ja) * 2008-01-29 2011-04-07 ラボラトワール・アシュエールア−ファルマ 子宮筋腫を治療するためのウリプリスタルの使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CONTRACEPTION, vol. 85, JPN6017007695, 2011, pages 480 - 488, ISSN: 0003658709 *
FERTIL STERIL, vol. Vol.92, No.3, Supplement, JPN7017000783, 2009, pages 60 - 61, ISSN: 0003658711 *
J PEDIATR ADOLESE GYNECOL, vol. 12, JPN7017000784, 1999, pages 23 - 26, ISSN: 0003658712 *
TOMIC VLATKA: "ORAL MICRONIZED PROGESTERONE COMBINED WITH VAGINAL PROGESTERONE GEL FOR LUTEAL SUPPORT", JOURNAL OF THE INTERNATIONAL SOCIETY OF GYNECOLOGICAL ENDOCRINOLOGY, vol. V27 N12, JPN5015005888, December 2011 (2011-12-01), pages 1010 - 1013, ISSN: 0003658710 *

Also Published As

Publication number Publication date
EA201491614A1 (ru) 2015-01-30
WO2013140372A1 (en) 2013-09-26
TW201400121A (zh) 2014-01-01
TW201832767A (zh) 2018-09-16
AU2013236960A1 (en) 2014-09-25
NZ630011A (en) 2016-12-23
EP2827873A1 (en) 2015-01-28
SG11201404921QA (en) 2014-10-30
CA2864073A1 (en) 2013-09-26
EP3363500A1 (en) 2018-08-22
MY172530A (en) 2019-11-29
US20150038476A1 (en) 2015-02-05
US10441534B2 (en) 2019-10-15
CN104203246A (zh) 2014-12-10
HK1199827A1 (en) 2015-07-24
GEP201706696B (en) 2017-07-10
JP2018109025A (ja) 2018-07-12
MX369520B (es) 2019-11-11
ZA201407575B (en) 2015-12-23
CO7111317A2 (es) 2014-11-10
EA031488B1 (ru) 2019-01-31
MX2014011487A (es) 2015-01-12
AU2013236960B2 (en) 2017-11-23
KR20140138824A (ko) 2014-12-04
EP2641602A1 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
Vannuccini et al. Role of medical therapy in the management of uterine adenomyosis
JP2018109025A (ja) 婦人科疾患の治療方法
JP5991988B2 (ja) 子宮内膜基底層の剥脱に関する疼痛の治療
JP4945052B2 (ja) 女性の性機能障害を治療するための方法および製剤
US8173626B2 (en) Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
ES2912929T3 (es) Métodos de tratamiento de fibromas uterinos y endometriosis
KR20120044307A (ko) 긴급 피임용 제약 조성물
CN103648503A (zh) 与子宫纤维瘤相关的过量月经出血的治疗
US20190262361A1 (en) Progesterone Receptor Modulators for Use in the Therapy of Uterine Fibroids
US20260115203A1 (en) Low-dose mifepristone for the treatment of endometriosis associated pain
Anita et al. Use of Progestogens in Clinical Practice of Obstetrics and Gynecology
Tsikouras et al. Causes of Visiting Teenagers in the Pediatric and Adolescence Examining Room
HK1188939A (zh) 基底子宫内膜异位相关疼痛的治疗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170908

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171011